Mouthwash Manufacturer Guide: B2B Sourcing, Compliance & Formulation Strategies for 2026–2035

Last Updated: May 18, 2026

Author: Felix Lee

Reviewed By: IColor Cosmetics Regulatory & Global Sourcing Team

Reading Time: 18 Minutes

A modern mouthwash manufacturer serves as a strategic technical partner rather than a simple bulk liquid supplier. In 2026 and across the coming decade, oral care production sits directly at the intersection of clinical science, international law, formulation chemistry, supply-chain resilience, and brand intellectual property protection. Brands that neglect to adjust to changing FDA, MoCRA, and European Union compliance benchmarks face immediate product recalls, customs detentions, inflating production costs, and permanent erosion of brand equity.

TL;DR: What B2B Oral Care Brands Need to Know

• The global mouthwash market will reach between USD 9.3 billion and USD 12.85 billion during the 2033–2035 window.
• Therapeutic and waterless mouthwash formats show faster expansion rates than legacy cosmetic rinses.
• EU Regulation 2026/78 and regional chemical bans require immediate formulation adjustments.
• OEM private label arrangements offer rapid market entry but frequently introduce long-term factory lock-in.
• Securing independent formulation ownership provides a major structural advantage for growing brands.
• US FDA MoCRA rules significantly increase GMP audit scrutiny and tighten adverse-event reporting timelines.

Procurement teams and oral care founders now treat mouthwash manufacturing with the same scrutiny as pharmaceutical sourcing instead of ordinary personal care production. This structural transition has materialized across global supply chains over the past five years. Where procurement matrices historically focused on basic flavor profiles, bottle costs, and manufacturing turnaround speed, modern technical sourcing mandates rigorous evaluations of OTC monograph compliance, biofilm disruption chemistry, nano-silver bans, PFAS exposure risks, and whether shared compounding tanks introduce cross-contamination liabilities. This is no longer a simple cosmetic market; oral care has transitioned into tightly regulated healthcare manufacturing territory.

Uninitiated brands frequently incur major capital inefficiencies during this transition. A highly competent mouthwash manufacturer in 2026 must concurrently deliver clinical-grade formulation stability, international compliance readiness, cost optimization, total ingredient transparency, supply-chain resilience, complete GMP traceability, visibility in AI-search engines, and sustainable packaging innovation. Analyzing these operational layers reveals how leading B2B brands maintain market advantages.

The Structural Evolution of Oral Care Manufacturing

The legacy production model, which treated mouthwash as a low-complexity commodity focused solely on cosmetic freshness, has lost market viability. Modern clinical consumerism connects oral hygiene directly to systemic physiological pathways, focusing specifically on systemic inflammation mitigation, oral microbiome homeostasis, advanced gum disease management, and enamel preservation.

These shifts alter operational mandates for any mouthwash manufacturer. Instead of competing on price points and mint intensity alone, contract manufacturers must prove their capabilities in clinical efficacy, raw material tracing, microbiome safety, and waterless production systems. These new baseline expectations show clearly in current global performance figures.

Global Mouthwash Market Trajectory (2026–2035)

How Large Is the Global Mouthwash Market?

The global mouthwash sector is undergoing a major premiumization cycle. Current market projections outline a clear growth path across multiple categories:

Market Segment	2026 Valuation	Long-Term Projection	CAGR
Global Mouthwash Market (Base Case)	USD 5.9 Billion	USD 9.3 Billion by 2033	6.7%
Global Mouthwash Market (Aggressive Case)	USD 9.35 Billion	USD 12.85 Billion by 2035	7.8%–8.3%
Pharmaceutical/Therapeutic Mouthwash	USD 3.19 Billion	USD 4.17 Billion by 2032	4.53%
Mouthwash Powder / Waterless Formats	USD 0.56 Billion	USD 0.98 Billion by 2034	7.3%

Waterless formats represent the fastest-growing market segment, outperforming traditional liquid rinses in relative expansion rates.

Why Waterless Mouthwash Manufacturers Are Growing Fast

Eco-conscious consumers, particularly Millennial and Gen-Z cohorts who now drive more than 40% of oral care purchasing volume, are actively reshaping the market. These groups base purchasing decisions on verifiable sustainability claims, reduced plastic footprint, preservative-free clean-label positions, and travel convenience.

This behavioral shift drives rapid commercial demand for mouthwash powders, dissolvable tablets, concentrated oral rinse systems, and single-use sachets. Several agile Asia-Pacific brands entered this waterless space early, securing clear market advantages through targeted digital commerce and cross-border marketplaces. Traditional oral care operations missed the fact that buyers view waterless oral care as both environmentally responsible and technologically superior, creating an excellent premium marketing position.

APAC Is Becoming the Fastest-Growing Oral Care Manufacturing Hub

The Asia-Pacific region will post the highest regional CAGR through 2032. This growth stems from a combination of expanding urban middle-class populations, rising disposable incomes, rapid digital commerce adoption, strong cultural connections to herbal oral care, and low current market penetration.

Adult mouthwash usage remains below 15% in major markets like India and Indonesia, compared to over 70% in the United States. This severe gap offers a massive volume opportunity for expanding brands. Consequently, contract manufacturing facilities across India, China, Thailand, Indonesia, and Vietnam are scaling up production of Ayurvedic formulations, natural rinse bases, small-format sachet packaging, and low-cost introductory SKUs. Brands such as Patanjali and Himalaya successfully accelerated category adoption by aligning liquid rinses with existing, culturally rooted daily herbal traditions. This represents a highly effective example of behavioral localization.

Formulation Chemistry & Cost Optimization Strategies

Why Traditional Mouthwash Formulas Are Becoming More Expensive

Conventional liquid mouthwash production relies heavily on polyol humectants, specifically glycerin and 70% aqueous sorbitol solutions, to construct the primary carrier phase. These raw materials improve mouthfeel, stabilize formulas against drying out when exposed to air, and ensure uniform texture.

However, these ingredients suffer from volatile global pricing. Procurement managers understand the financial damage caused by sudden glycerin price spikes during broader supply-chain disruptions. To protect manufacturing margins, brands must deploy advanced alternative formulation chemistry.

Carrageenan as a Humectant Replacement Strategy

Recent patent filings demonstrate that specific carrageenans serve as an effective substitute for expensive polyol networks. The primary technical benchmark requires these carrageenans to achieve a dynamic viscosity threshold of $\eta \ge 20 \text{ mPa}\cdot\text{s}$ in a 1.5% aqueous solution at 25°C.

In practice, these carrageenans stabilize water activity, minimize evaporation losses, and match required viscosity profiles, allowing formulators to remove significant portions of the glycerin or sorbitol base. These specialized carrageenan networks restrict product evaporation to $\text{Water Loss} \le 0.75\%$ when exposed to ambient air for 30 minutes at room temperature under 50% relative humidity. This formulation adjustments acts as an important lever for cost reduction, particularly for high-volume private-label operations facing downward margin pressure from major retail clients.

Biofilm Disruption Is the Real Engineering Challenge

Standard consumer marketing claims that mouthwash simply eliminates bacteria, but true therapeutic oral chemistry requires a more sophisticated approach. Pathogenic oral bacteria construct a dense extracellular polymeric substance (EPS) matrix, building a tough physical shield that resists standard antibacterial agents.

To break through this plaque biofilm, advanced contract manufacturers use hops beta acids derived from Humulus lupulus extracts. When formulators combine hops beta acids (ranging from 0.01% to 10% by weight) with amino acids like glycine or specific fluoride salts, the system shows clear synergistic activity. This combination breaks the EPS matrix, allowing active antibacterial agents to interact directly with enamel surfaces. This approach improves anti-caries and anti-gingivitis outcomes without using high, potentially hazardous fluoride concentrations that would otherwise force a prescription-only regulatory classification.

Essential Oils vs. Chlorhexidine: The Clinical Tradeoff

Choosing the primary antibacterial agent involves clear clinical tradeoffs. Traditional chemical antiseptics, such as chlorhexidine gluconate, offer powerful antimicrobial action but cause severe long-term side effects, including dark tooth staining, mucosal dryness, altered taste perception, and oral microbiome dysbiosis. Clinical professionals at recent oral care sourcing events note that while chlorhexidine delivers short-term results, poor patient compliance limits its long-term utility.

This clinical friction drives the market toward natural botanical alternatives. Modern clean-label mouthwash manufacturers use essential oils rich in terpenes and phenolic compounds, including peppermint (menthol), clove (eugenol), tea tree, thyme, eucalyptus, and myrrh. These plant extracts match the raw antibacterial performance of chlorhexidine without triggering oral tissue staining or opportunistic dysbiosis. Furthermore, they protect the protective natural enzymes in human saliva, such as lactoferrin and lysozyme. Preserving the oral microbiome’s natural self-regulating capacity serves as an excellent marketing differentiator for premium brands.

Chemical & Regulatory Ingredient Matrix

Ingredient	Primary Function	B2B Implication	Regulatory Context
Glycerin/Sorbitol	Humectant, carrier phase, mouthfeel	Expensive, volatile global raw material pricing	Globally accepted cosmetic and drug inactive excipient
Select Carrageenans	Thickener, water binder, humectant substitute	Reduces production costs, stabilizes water retention	Approved food-grade and cosmetic thickener
Sodium Fluoride	Anti-caries active, remineralization	Requires highly precise batch dosing systems	Mandates US FDA OTC Drug Facts labeling
Hops Beta Acids	Biofilm penetration, anti-caries synergy	Premium natural active requiring specialized sourcing	Allowed globally as a natural botanical extract
Chlorhexidine Digluconate	High-potency antimicrobial active	Long-term use causes noticeable tooth staining	Restricts final product to Rx/Professional channels
Cetylpyridinium Chloride (CPC)	Antiseptic agent, plaque control	Stable in emulsion; requires insoluble flavor adjustments	Approved under US FDA OTC antiseptic monograph
Eugenol (Clove Oil)	Natural analgesic, anti-inflammatory	Strong sensory profile; requires careful balancing	GRAS status; subject to fragrance allergen labeling
Hexyl Salicylate	Fragrance compound, top-note stabilizer	Triggers severe compliance failure in the European Union	Banned in EU oral care above 0.001% as of May 1, 2026

OEM vs. ODM: The Strategic Manufacturing Decision

The Appeal of Turnkey OEM Mouthwash Manufacturing

Original Equipment Manufacturing (OEM), or private labeling, offers lowest initial capital requirements, fast speed-to-market, and access to pre-stabilized, regulatory-cleared formulas. Typical contract manufacturing structures provide clear startup advantages:

• Minimum Order Quantities (MOQs): 500 to 1,000 units.
• Production Lead Times: 2 to 4 weeks.
• Formulation Risk: Minimal, due to pre-existing stability testing and compliance paperwork.
• Low-Capital Variants: Wholesale options with zero MOQs, bulk liter configurations, or plain unlabeled bottles for local dental networks.

While these turnkey frameworks help emerging brands enter the market quickly, they include an expensive hidden liability.

The Problem With Manufacturer-Owned Formulas

In standard turnkey OEM arrangements, the contract manufacturer retains total ownership of the underlying formulation intellectual property. This operational setup introduces major risks:

• The brand cannot transfer manufacturing to an alternative facility to resolve capacity issues.
• Direct market competitors can buy the exact same formulation from the same facility.
• The brand loses all long-term pricing and margin negotiation leverage.
• Reverse-engineering a factory-owned formula later requires significant capital and time.

Many digital brands scale rapidly through online marketing channels, only to find themselves trapped when their single compounding facility implements an unexpected 18% increase in production pricing. At that stage, the brand has no structural leverage.

Why Independent Formulators Matter

To avoid this supply chain trap, sophisticated oral care brands now work with independent cosmetic chemists to build a private formulation portfolio before contacting factories. This model requires a higher upfront investment:

• Independent Chemist Rates: Approximately USD 500 per hour.
• Initial Concept Engagement: 4 to 10 hours of initial analysis.
• Validation Timeline: 6 to 12 months for comprehensive stability, microbiological, and safety testing.
• Contract Manufacturing MOQs: 5,000 to 10,000 units to justify custom compound line setups.

Despite the higher initial costs, owning an open-source formulation dossier protects long-term manufacturing flexibility, ensures total ingredient transparency, safeguards profit margins, and builds real brand equity that corporate buyers and investors expect during due diligence.

B2B Sourcing Scenario Matrix

Scenario	Recommended Sourcing Model	Key Operational Considerations
Sustainable Startup Launch	Independent R&D followed by ODM contract bidding	Secure formulation IP ownership before requesting factory quotes
Ayurvedic Volume Sourcing	Vetted sourcing specialists located in India	Verify local GMP, ISO, and FSSAI/Ayurvedic regulatory licensing
OTC Medical Mouthwash Import	Registered Importers of Record with FDA expertise	Maintain active NDC logs and submit mandatory FDA prior notices
Clinical Trial / Validation Run	Direct wholesale factory purchasing (e.g., Lingora®)	Low capital requirement for product market validation runs

FDA Regulation: Why Mouthwash Is No Longer “Simple Cosmetics”

Cosmetic vs. OTC Drug Classification

The United States Food and Drug Administration determines mouthwash classification based entirely on intended use, evaluated through labeling claims, marketing text, and active ingredient properties. This creates a strict legal boundary:

• Cosmetic Mouthwash: Products designed solely to clean the oral cavity, freshen breath, or remove superficial surface stains do not require pre-market approval.
• OTC Therapeutic Drugs: Rinses that claim to reduce plaque biofilm, prevent dental caries through fluoride ions, treat gingivitis, or relieve dentin sensitivity are classified as drugs.

OTC Drug Monographs Increase Compliance Costs

Therapeutic mouthwashes must strictly match US FDA OTC Drug Monographs, which define approved active concentrations and require formal Drug Facts labeling. Operating within this framework adds an estimated 3% to 6% increase to the final Cost of Goods Sold (COGS) due to continuous analytical testing, batch validation, and regulatory documentation requirements. Brands frequently miscalculate this regulatory overhead during initial product budgeting.

MoCRA Changed the Entire US Compliance Landscape

The Modernization of Cosmetics Regulation Act of 2022 fundamentally reshaped federal oversight for all cosmetic products sold within the United States. Under current MoCRA enforcement guidelines, brands must track severe operational mandates:

• Facility Registration: Manufacturing sites must register with the FDA and match standardized Good Manufacturing Practices (GMP) modeled on ISO 22716.
• Product Listing: Brands must submit an annual, detailed ingredient list for every SKU.
• Safety Substantiation: Section 608 requires brands to maintain explicit, scientific safety records for all formulations.
• Adverse Event Reporting: Section 605 requires brands to report any serious adverse health events to the FDA within 15 days and preserve consumer complaint files for six years.
• Records Access: The FDA holds expanded authority to inspect internal facility records if a product is suspected of causing serious public health issues.

EU Regulation 2026/78 Is Forcing Massive Reformulations

The European Union’s Regulation 2026/78 aligns cosmetic compliance with strict carcinogenic, mutagenic, or toxic for reproduction (CMR) classifications under the 21st Adaptation to Technical Progress (ATP) / Omnibus VIII framework. Unlike typical legislative updates, this regulation provides no transition period for warehouse inventory: all non-compliant products had to be removed from European retail shelving by May 1, 2026.

Hexyl Salicylate Became a Major Industry Problem

Hexyl Salicylate serves as a common fragrance fixative and top-note component across standard mint flavor profiles. Under the new EU rules, it is capped at a maximum concentration of 0.001% in oral care products and banned entirely in products intended for children under three years of age. Because this threshold is exceptionally low, most global mouthwash brands must completely reformulate their core flavor systems to remain compliant in Europe.

Nano-Silver Restrictions Explained

The European Union enforces specific limits based on silver particle dimensions:

• Prohibited Scales: Nano-scale silver ($1\text{ nm} < d \le 100\text{ nm}$) is completely banned due to cellular accumulation risks. Massive physical silver particles ($d \ge 1\text{ mm}$) are similarly prohibited.
• Restricted Scales: Intermediate silver powder ($100\text{ nm} < d < 1\text{ mm}$) is restricted to a maximum concentration of 0.05% in toothpaste and mouthwash.

This rule creates immediate reformulation requirements for premium teeth-whitening rinses that previously used colloidal silver suspensions.

PFAS Bans Are Expanding Beyond the EU

France’s national ban on per- and polyfluoroalkyl substances (PFAS) in cosmetics takes full effect on January 1, 2026, prohibiting the manufacture, import, or sale of any personal care product containing fluorinated compounds. Procurement teams must secure signed “PFAS-Free” declarations from chemical suppliers to protect Western European distribution chains from immediate border seizures.

GMP Auditing: What Serious Buyers Actually Look For

Paper GMP certificates no longer provide adequate liability protection. Competent procurement teams now conduct on-site physical audits focusing on cleaning validation studies, line clearance records, and shared compounding tank risk management.

The Shared Tank Contamination Problem

Recent FDA warning letters highlight the severe risks of cross-contamination in shared facilities where cosmetic rinses and therapeutic OTC batches are run through identical compounding lines. In a notable enforcement case, an oral care manufacturer caused hormone cross-contamination in children’s products because of inadequate cleaning validation. Shared compounding tanks allowed active chemical carryover between separate product runs.

$$\text{Shared Compounding Line} \xrightarrow{\text{Inadequate Cleaning Validation}} \text{Active Active Carryover} \xrightarrow{\text{Batch Contamination}} \text{Product Recall \& Legal Liability}$$

To mitigate this risk, serious B2B buyers mandate dedicated OTC manufacturing lines, systematic trace-residue testing, worst-case soil clearance validation, and complete toxicological batch tracking. If contamination occurs, regulatory authorities hold the brand owner legally liable, not the contract factory.

“Ghost Brewing” and Store-Brand Mouthwash Reality

The term “ghost brewing” describes a common industry practice where a single large contract manufacturing facility produces both a premium national brand (such as Listerine) and a retailer’s generic store brand (such as Walmart’s Equate or Target’s Up&Up) using identical compounding machinery and bottling lines. However, this does not mean the liquid contents are chemically identical.

Contract manufacturers build private-label store brands to a retailer’s minimum technical specifications to keep costs as low as possible. While the active ingredient percentages match the official OTC monograph to allow “compare-to” labeling, the inactive components, excipients, and flavor bases use lower-grade ingredients. This cheaper chemical balancing often results in a harsher burning sensation, poorer mucosal tissue tolerability, and faster flavor separation over time. “Compare-to” labeling serves as a marketing tool, not proof of identical formulation quality or raw material purification levels.

Importing Mouthwash: The Customs Risks Most Brands Miss

Importing liquid oral care products into major consumer markets includes significant border entry risks. Because therapeutic rinses operate under OTC drug rules, customs entries require active FDA facility registrations, valid National Drug Code numbers, and verified prior notice filings submitted through a registered Importer of Record.

Standard commercial customs brokers frequently mismanage these technical filings. Partnering with specialized FDA customs brokers ensures that foreign lab data matches current monograph requirements, preventing expensive border detentions.

Why Nearshoring Is Accelerating

Tariff adjustments, ocean freight volatility, and shifting geopolitical landscapes are driving global oral care operations toward regional nearshoring models. Brands increasingly split production: nearshoring local bottling and OTC filling lines close to primary consumer hubs while using highly vetted offshore contract factories (such as GMP-certified operations in India) to handle bulk botanical extraction and raw chemical compounding. This approach reduces tariff exposure, shortens delivery lead times, and maintains tight control over regional regulatory updates.

Strategic Action Plan for Oral Care Brands

1. Execute Immediate Regulatory and Formula Audits: Review all international product labels, marketing claims, and ingredient sheets. Verify that formulas distributed in Europe do not exceed the 0.001% Hexyl Salicylate cap, contain no nano-silver particles, and exclude banned preservatives ahead of upcoming enforcement deadlines.
2. Secure Total Formulation Ownership: Stop relying on a contract manufacturer’s proprietary turnkey formulations. Contract an independent oral care formulator to build a custom, open-source formulation portfolio. Owning your intellectual property allows you to shift manufacturing smoothly if a factory raises prices or experiences quality control failures.
3. Validate Factory GMP Protocols Thoroughly: Move beyond paper compliance certifications. Demand a contract manufacturer’s full cleaning validation records, evaluate their separation protocols for shared equipment lines, and review their documented MoCRA adverse-event tracking infrastructure.
4. Diversify Sourcing Across Multiple Regions: Protect your enterprise from single-source vulnerabilities. Deploy a multi-facility manufacturing structure that uses localized onshore packaging operations combined with vetted, cost-effective offshore ingredient compounders.

FAQ: B2B Mouthwash Manufacturing & Sourcing

Q1: How can global brands mitigate formulation compliance risks under the strict deadlines of EU Regulation 2026/78 and emerging PFAS restrictions?

Short Answer: Run immediate flavor, preservative, and surfactant audits with raw material suppliers to eliminate restricted ingredients before shipping to Europe.

Detailed Guidance: Brands must require complete formulation disclosures from fragrance houses to confirm Hexyl Salicylate levels fall below 0.001%. Replace older o-Phenylphenol preservative systems with alternative organic acids like sodium benzoate. Finally, secure written “PFAS-Free” certifications from compounders ahead of French regulatory deadlines to protect inbound container shipments.

Q2: What are the critical elements of a B2B GMP facility audit to prevent cross-contamination and ensure regulatory readiness under FDA’s MoCRA and OTC Drug rules?

Short Answer: Audit worst-case cleaning validation protocols, physical line clearance documentation, and serious adverse-event reporting pipelines.

Detailed Guidance: Do not rely on basic paper certifications. Review the facility’s analytical testing methods for cleaning shared compounding tanks, ensuring they track highly potent or poorly soluble residues. Confirm total physical line separation between everyday cosmetics and OTC therapeutic drugs, and verify the facility can process and deliver serious consumer complaints within the mandatory 15-day federal reporting window.

Q3: How should a startup or mid-market oral care brand navigate the technical and financial tradeoffs of hiring an independent formulator versus using a turnkey private label manufacturer’s in-house R&D?

Short Answer: Use turnkey OEM formulas for short-term market testing, but invest in an independent formulator to secure intellectual property ownership for long-term brand scaling.

Detailed Guidance: Turnkey OEM models compress upfront costs and shorten lead times to a few weeks, but leaving formulation ownership with the factory creates single-source lock-in and eliminates future pricing leverage. Spending capital upfront on an independent chemist (~USD 500 per hour) yields an open-source, transferable formulation dossier. This allows competitive bidding across multiple contract facilities and protects your long-term business valuation.

Q4: Is “ghost brewing” (private label sharing) a viable strategy for store-brand mouthwash, and do these products actually match the formulation quality of premium national brands?

Short Answer: Ghost brewing works well for low-cost retail positioning, but the underlying formulations use cheaper inactive excipients built to minimum retail specifications.

Detailed Guidance: A single contract plant routinely bottles both premium national brands and generic store brands using the same machinery. However, to preserve retail margins, store-brand formulations use lower-grade inactive ingredients and cheaper flavor bases. While they maintain legal active equivalency on the Drug Facts label, the lower excipient quality frequently leads to a harsher taste profile, lower tissue tolerability, and reduced emulsion stability over time.

Q5: What logistics, customs, and global sourcing strategies are essential for importing bulk or finished oral care products to avoid detention at the border?

Short Answer: Route all international commercial shipments through specialized FDA customs brokers, and register active National Drug Codes for all therapeutic SKUs.

Detailed Guidance: General logistics brokers often fail to navigate the prior notice documentation required for OTC therapeutic liquid imports. Brands must verify that their overseas manufacturing facilities hold active FDA registrations and that every incoming batch perfectly matches current monograph standards. When sourcing bulk materials from high-volume regions like India, hire localized sourcing agents to physically audit local factories for international GMP and ISO compliance before starting mass production.

Final Thoughts: The Future Belongs to Advanced Mouthwash Manufacturers

The global oral care sector no longer competes purely on basic freshness claims or packaging aesthetics. The next generation of market leaders will build competitive advantages through formulation science, total compliance readiness, microbiome preservation, and highly resilient sourcing models. Brands that treat mouthwash as an ordinary personal care commodity are falling behind. If you are developing an oral care brand across the 2026–2035 window, your mouthwash manufacturer serves as your critical regulatory shield, formulation strategist, and scalability engine. Choose your manufacturing partner with care.

About the Author

Felix Lee is the CEO of IColor Cosmetics, specializing in OEM/ODM cosmetic manufacturing, oral-care formulation strategy, international sourcing, and regulatory-compliant product development. Felix works closely with global beauty and healthcare brands on private-label manufacturing, formulation scalability, GMP sourcing audits, and international compliance strategy across North America, Europe, and Asia-Pacific.

Expert Regulatory Disclaimer

This article is intended for educational and industry research purposes only and does not constitute legal, regulatory, medical, or customs compliance advice. Regulatory frameworks including FDA MoCRA, OTC Drug Monographs, EU Regulation 2026/78, and PFAS restrictions continue to evolve. Brands should consult qualified regulatory counsel, toxicologists, and import specialists before commercializing oral-care products internationally.